$Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China$

Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China

Background: Eltrombopag (ELT), a thrombopoietin receptor agonist (TPO-RA), has been approved for relapsed/refractory aplastic anemia (AA). However, data on avatrombopag (AVA), another TPO-RA, are limited, and the comparisons between the two TPO-RAs are lacking. Objectives: We aimed to compare the ef...

Full description

Bibliographic Details
Main Authors:	Zhuxin Zhang, Qinglin Hu, Chen Yang, Miao Chen, Bing Han
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-09-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207231191310

Similar Items

PB2041: COMPARISON OF ELTROMBOPAG AND AVATROMBOPAG IN THE TREATMENT OF REFRACTORY/RELAPSED APLASTIC ANEMIA, A SINGLE CENTER STUDY IN CHINA
by: Zhuxin Zhang, et al.
Published: (2023-08-01)

PB2479: ELTROMBOPAG, BUT NOT AVATROMBOPAG, REGULATES BONE MARROW MICROENVIRONMENT MIMICKING APLASTIC ANEMIA THROUGH DOWN-REGULATION OF FERROPTOSIS INHIBITOR
by: Jiang Ji, et al.
Published: (2023-08-01)

Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia
by: Hong Chang, et al.
Published: (2023-11-01)

Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial
by: Jiang Ji, et al.
Published: (2023-09-01)

Correlation of the Plasma Concentration of Eltrombopag With Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Centre Study in China
by: Wei Zuo, et al.
Published: (2020-11-01)

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial
by: Ziqi Wan, et al.
Published: (2023-12-01)

Adding cyclosporin A to eltrombopag for aplastic anemia secondary to chemotherapy for solid cancers
by: Ziqi Wan, et al.
Published: (2023-05-01)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
by: Ayşe Işık, et al.
Published: (2013-09-01)

Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study
by: Zhuxin Zhang, et al.
Published: (2023-12-01)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
by: Abdul Muqtadir Abbasi, et al.
Published: (2022-01-01)

Role of eltrombopag in severe aplastic anemia treatment in children
by: Min-Yu Su, et al.
Published: (2021-11-01)

PB1949: ELTROMBOPAG IN CHINESE PATIENTS WITH REFRACTORY OR RELAPSED SEVERE APLASTIC ANEMIA: A NON-RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF ELTROMBOPAG
by: H. Chang, et al.
Published: (2022-06-01)

PB2048: HEMATOLOGIC RECOVERY INDUCED BY AVATROMBOPAG IN SAA REFRACTORY OR INTOLERANT TO IMMUNOSUPPRESSIVE THERAPY COMBINED WITH ELTROMBOPAG
by: Xiaoqing Liu, et al.
Published: (2023-08-01)

Efficacy of eltrombopag with immunosuppressive therapy for children with acquired aplastic anemia
by: Yufei Zhao, et al.
Published: (2023-01-01)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
by: Akiko Konishi, et al.
Published: (2019-01-01)

Current evidence and the emerging role of eltrombopag in severe aplastic anemia
by: Beatrice Drexler, et al.
Published: (2021-03-01)

P763: EFFICACY AND SAFETY OF AVATROMBOPAG IN THE TREATMENT OF TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA
by: Ting Zhang, et al.
Published: (2023-08-01)

Paroxysmal nocturnal hemoglobinuria‐phenotype cells predict a good response to eltrombopag in patients with refractory aplastic anemia
by: Ken Ishiyama, et al.
Published: (2020-07-01)

HEMATOLOGIC RECOVERY INDUCED BY ELTROMBOPAG IN PATIENT WITH APLASTIC ANEMIA AFTER TEMOZOLOMIDE
by: ACP Silva, et al.
Published: (2023-10-01)

P811: A SINGLE CENTER HISTORICAL CONTROL STUDY OF ELTROMBOPAG ADDED TO IMMUNOSUPPRESSIVE THERAPY FOR SEVERE APLASTIC ANEMIA IN CHILDREN
by: B. yang, et al.
Published: (2022-06-01)

Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure
by: Abdul Rehman Arif, et al.
Published: (2022-11-01)

NATIONAL EXPERIENCE WITH IMMUNOSUPPRESSIVE THERAPY AND ELTROMBOPAG IN CHILDREN WITH APLASTIC ANEMIA- REAL WORLD DATA
by: Katarzyna Pawelec, et al.
Published: (2023-12-01)

The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review
by: Maria Maddalena Marrapodi, et al.
Published: (2023-04-01)

Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia
by: Yihong Guan, et al.
Published: (2022-02-01)

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
by: Tremblay G, et al.
Published: (2019-11-01)

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag
by: Ruixin Li, et al.
Published: (2022-05-01)

Avatrombopag for the salvage treatment of platelet transfusion refractoriness
by: Yuehong Qin, et al.
Published: (2024-03-01)

Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia
by: Darren Kelly, et al.
Published: (2020-03-01)

Immunosuppressive therapy in patients with aplastic anemia: a single-center retrospective study.
by: Hasan Jalaeikhoo, et al.
Published: (2015-01-01)

Acquired aplastic anemia in childhood: single-center experience
by: M. Bilici, et al.
Published: (2020-10-01)

Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
by: Limin Liu, et al.
Published: (2022-08-01)

Safety and efficacy of eltrombopag in patients with aplastic anemia: a systematic review and meta-analysis of randomized controlled trials
by: Huaipeng Guo, et al.
Published: (2024-12-01)

Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis
by: Yan Zhang, et al.
Published: (2024-04-01)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
by: Margherita Vieri, et al.
Published: (2023-06-01)

S184: SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA
by: Ashvind Prabahran, et al.
Published: (2023-08-01)

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials
by: Stephane Heritier, et al.
Published: (2024-01-01)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
by: R. Li, et al.
Published: (2022-06-01)

P766: ELTROMBOPAG EFFECTIVELY ALLEVIATES APLASTIC ANEMIA THROUGH REDUCING AKT PROTEIN STABILITY AND MODULATING T LYMPHOCYTE SUBSETS
by: Zenghua Lin, et al.
Published: (2023-08-01)

PB2069: ELTROMBOPAG WITH IMMUNO SUPPRESSIVE THERAPY IN SEVERE ACQUIRED APLASTIC ANEMIA IN CHILDREN AND ADOLESCENTS: A MONOCENTRIC EXPERIENCE
by: Nesrine Ben Sayed, et al.
Published: (2023-08-01)

Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature
by: Marta Bortolotti, et al.
Published: (2022-03-01)